Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice

Neuropharmacology
A VigoloM Marti

Abstract

JWH-018 is a synthetic CB1 and CB2 agonist illegally marketed as products named "Spice" or "herbal blend" for its psychoactive effects which are much higher than those produced by cannabis. In the last year, the European Monitoring Centre for Drugs and Drug Addiction reported to the Italian National Early Warning System the seizure of plant material containing new halogenated derivatives of JWH-018 (JWH-018 Cl and JWH-018 Br). The present study aimed to investigate the in vitro and in vivo activity of these two new synthetic cannabinoids in mice. In vitro competition binding experiments performed on mouse and human CB1 receptors revealed a high affinity and potency of the halogenated compounds. Synthetic cannabinoids (0.01-6 mg/kg i.p.) impaired motor activity and induced catalepsy in mice and their effects were more severe with respect to those evoked by Δ(9)-THC. Moreover, they increased the mechanical and thermal pain threshold and induced a marked hypothermia. It is interesting to note that whereas high doses of JWH-018 cause seizures, myoclonia and hyperreflexia, the halogenated compounds, in particular JWH-018Br, were less effective. Behavioral and neurological changes were prevented by the selective CB1 receptor antagoni...Continue Reading

References

Aug 17, 2002·Pharmacology & Therapeutics·J Michael Walker, Susan M Huang
Jul 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Matteo MartiMichele Morari
Oct 19, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sophie J GovaertsDidier M Lambert
Mar 12, 2005·The AAPS Journal·Spyros P NikasAlexandros Makriyannis
Oct 21, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Matteo MartiMichele Morari
Feb 8, 2007·The Journal of Pharmacology and Experimental Therapeutics·Saoirse E O'SullivanSheila M Gardiner
Nov 13, 2007·British Journal of Pharmacology·J Guindon, A G Hohmann
Dec 17, 2008·Trends in Pharmacological Sciences·Armen N AkopianKenneth M Hargreaves
Feb 4, 2009·Journal of Mass Spectrometry : JMS·Volker AuwärterNerea Ferreirós
Aug 29, 2009·Neuroscience and Biobehavioral Reviews·Francis McGlone, David Reilly
Oct 20, 2009·Cell·Allan I BasbaumDavid Julius
Feb 2, 2010·Forensic Science International : Synergy·Nahoko UchiyamaYukihiro Goda
Nov 6, 2010·The European Journal of Neuroscience·Alina TelibanWilfrid Jänig
Jan 22, 2011·Annals of Emergency Medicine·Joshua R SimmonsBrandon K Wills
Oct 6, 2011·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·J LapointJ H Moran
Dec 1, 2011·Drug and Alcohol Dependence·Jenny L WileyJohn W Huffman
Dec 14, 2011·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Aaron B Schneir, Todd Baumbacher
May 9, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kathryn A SeelyLiana Fattore
Jul 11, 2012·Drug and Alcohol Dependence·Jason M WiebelhausLaura E Wise
Oct 19, 2012·Behavioural Pharmacology·Carol A ParonisAlexandros Makriyannis
Apr 23, 2013·Pharmacology, Biochemistry, and Behavior·Peter J McLaughlinJohn D Salamone
May 3, 2013·International Journal of Legal Medicine·Frank MusshoffVolker Auwärter

❮ Previous
Next ❯

Citations

Jan 19, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andrea OssatoMatteo Marti
May 20, 2015·Neuroscience·A OssatoM Marti
Aug 15, 2019·British Journal of Pharmacology·Shivani SachdevMark Connor
Jul 12, 2017·Behavioural Pharmacology·Nicholas PintoriMaddalena Mereu
Feb 27, 2020·Pharmacology Research & Perspectives·Shivani SachdevMark Connor
Sep 8, 2017·Frontiers in Psychiatry·Aviv M WeinsteinEdythe D London
Jul 30, 2018·International Journal of Legal Medicine·Federica FotiFabio De-Giorgio
Jan 3, 2020·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·Anna-Maria SmolyakovaRobert B Laprairie
Jan 19, 2019·Brain Sciences·Balapal S Basavarajappa, Shivakumar Subbanna
Jun 14, 2019·Frontiers in Pharmacology·Richard C KevinSamuel D Banister
Jan 10, 2020·Frontiers in Pharmacology·Cristina MilianoMaria Antonietta De Luca
Aug 18, 2017·Case Reports in Cardiology·E Ul HaqB Omar
Nov 19, 2019·Frontiers in Neuroscience·Sabrine BilelMatteo Marti
May 2, 2020·International Journal of Legal Medicine·Fabio De-GiorgioMatteo Marti
Feb 14, 2020·International Journal of Molecular Sciences·Monia LenziMatteo Marti
Sep 10, 2020·Brain Sciences·Liana FattoreMaria Paola Castelli
Nov 4, 2017·Pharmacology & Therapeutics·Laura HondebrinkRemco H S Westerink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here